The offer of $19.60 a share, represents a premium of 83% to the Swedish pharma’s closing price on Monday, and the board has unanimously recommended that shareholders accept the deal.
The offer of $19.60 a share, represents a premium of 83% to the Swedish pharma’s closing price on Monday, and the board has unanimously recommended that shareholders accept the deal.